These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 12735911)

  • 1. Clinical features of malignant syndrome in Parkinson's disease and related neurological disorders.
    Harada T; Mitsuoka K; Kumagai R; Murata Y; Kaseda Y; Kamei H; Ishizaki F; Nakamura S
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S15-23. PubMed ID: 12735911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A collaborative study on the malignant syndrome in Parkinson's disease and related disorders.
    Takubo H; Harada T; Hashimoto T; Inaba Y; Kanazawa I; Kuno S; Mizuno Y; Mizuta E; Murata M; Nagatsu T; Nakamura S; Yanagisawa N; Narabayashi H
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S31-41. PubMed ID: 12735913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Withdrawal of levodopa and other risk factors for malignant syndrome in Parkinson's disease.
    Hashimoto T; Tokuda T; Hanyu N; Tabata K; Yanagisawa N
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S25-30. PubMed ID: 12735912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant syndrome in Parkinson's disease: concept and review of the literature.
    Mizuno Y; Takubo H; Mizuta E; Kuno S
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S3-9. PubMed ID: 12735909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention and treatment of malignant syndrome in Parkinson's disease: a consensus statement of the malignant syndrome research group.
    Ikebe S; Harada T; Hashimoto T; Kanazawa I; Kuno S; Mizuno Y; Mizuta E; Murata M; Nagatsu T; Nakamura S; Takubo H; Yanagisawa N; Narabayashi H
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S47-9. PubMed ID: 12735915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum creatine kinase is elevated in patients with Parkinson's disease: a case controlled study.
    Takubo H; Shimoda-Matsubayashi S; Mizuno Y
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S43-6. PubMed ID: 12735914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of malignant syndrome associated with a parkinsonism patient.
    Sanga M; Nomura S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2003 Apr; 23(2):91-5. PubMed ID: 12762221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroleptic malignant syndrome in advanced Parkinson's disease.
    Gordon PH; Frucht SJ
    Mov Disord; 2001 Sep; 16(5):960-2. PubMed ID: 11746631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroleptic malignant syndrome without neuroleptics.
    Ong KC; Chew EL; Ong YY
    Singapore Med J; 2001 Feb; 42(2):85-8. PubMed ID: 11358199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small (autonomic) and large fiber neuropathy in Parkinson disease and parkinsonism.
    de Araújo DF; de Melo Neto AP; Oliveira ÍS; Brito BS; de Araújo IT; Barros IS; Lima JW; Horta WG; Gondim Fde A
    BMC Neurol; 2016 Aug; 16():139. PubMed ID: 27530902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroleptic malignant syndrome in parkinsonian patients: risk factors.
    Kuno S; Mizuta E; Yamasaki S
    Eur Neurol; 1997; 38 Suppl 2():56-9. PubMed ID: 9387804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevention and treatment of malignant syndrome in patients with Parkinson's disease].
    Kuno S
    Nihon Rinsho; 2004 Sep; 62(9):1721-4. PubMed ID: 15462391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported autonomic symptoms in Parkinson disease.
    Verbaan D; Marinus J; Visser M; van Rooden SM; Stiggelbout AM; van Hilten JJ
    Neurology; 2007 Jul; 69(4):333-41. PubMed ID: 17646625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prolonged QTc intervals in Parkinson's disease--relation to sudden death and autonomic dysfunction].
    Ishizaki F; Harada T; Yoshinaga H; Nakayama T; Yamamura Y; Nakamura S
    No To Shinkei; 1996 May; 48(5):443-8. PubMed ID: 8672303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When do the symptoms of autonomic nervous system malfunction appear in patients with Parkinson's disease?
    De Luka SR; Svetel M; Pekmezović T; Milovanović B; Kostić VS
    Vojnosanit Pregl; 2014 Apr; 71(4):346-51. PubMed ID: 24783414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of methyprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease.
    Clarke CE
    J Neurol Neurosurg Psychiatry; 2004 Mar; 75(3):510-1; author reply 511. PubMed ID: 14966183
    [No Abstract]   [Full Text] [Related]  

  • 17. Symptoms of autonomic failure in Parkinson's disease: prevalence and impact on daily life.
    Magerkurth C; Schnitzer R; Braune S
    Clin Auton Res; 2005 Apr; 15(2):76-82. PubMed ID: 15834763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroleptic malignant syndrome in a patient with Parkinson's disease: a case study.
    Ward C
    J Neurosci Nurs; 2005 Jun; 37(3):160-2. PubMed ID: 16001822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autonomic Function Tests and MIBG in Parkinson's Disease: Correlation to Disease Duration and Motor Symptoms.
    Rocchi C; Pierantozzi M; Galati S; Chiaravalloti A; Pisani V; Prosperetti C; Lauretti B; Stampanoni Bassi M; Olivola E; Schillaci O; Stefani A
    CNS Neurosci Ther; 2015 Sep; 21(9):727-32. PubMed ID: 26205884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study.
    Williams DR; Lees AJ
    Lancet Neurol; 2005 Oct; 4(10):605-10. PubMed ID: 16168928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.